Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
World Bleeding Disorders Treatment Market 2017-2027 | ||
By: PR Newswire Association LLC. - 22 Sep 2017 | Back to overview list |
|
LONDON, September 22, 2017 /PRNewswire/ -- Forecast and Analysis by Indication (Haemophilia A, Haemophilia B, Von Willebrand Disease), Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants) and Geography Bleeding Disorder Treatment - our new study reveals trends, R&D progress, and predicted revenues: (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg ) Where is the Bleeding Disorder Treatment market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover how to stay ahead:
Forecasts to 2027 and other analyses reveal the commercial prospects:
Discover sales predictions for the world market and submarkets:
Bleeding Disorder Treatments, by Indication:
Bleeding Disorder Treatments, by Drug Class:
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 19 leading national markets: • North America: • South America: • Europe: • Asia-Pacific: • Rest of World (RoW): The report also includes profiles and for some of the leading companies in the Bleeding Disorder Treatment market, with a focus on this segment of these companies' operations. There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, China, India and Australia in particular, will continue to achieve high revenue growth to 2027. Leading companies and the potential for market growth:
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the Bleeding Disorder Treatment Market report helps you:
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else:
Visiongain's study is for everybody needing commercial analyses for the Bleeding Disorder Treatment market and leading companies. You will find data, trends and predictions. Get our report today World Bleeding Disorders Treatment Market 2017-2027: Forecast and Analysis by Indication (Haemophilia A, Haemophilia B, Von Willebrand Disease), Drug Class (Plasma-Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants) and Geography. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100 Or click on https://www.visiongain.com/Report/1996/World-Bleeding-Disorders-Treatment-Market-2017-2027 Companies Mentioned in the Report Abbott Laboratories AbbVie, Inc. Aetna, Inc. Alkermes Plc Amarin Corp. Plc Amgen, Inc. Array BioPharma, Inc. Associates Of Cape Cod Inc. Astex Pharmaceuticals Inc. AstraZeneca Plc Bayer AG Bayer Corporation Bayer HealthCare AG Bayer Schering Pharma Aktiengesellschaft BioMarin Pharmaceutical, Inc. Biotest AG Bristol-Myers Squibb Co. Cardax, Inc. Cardinal Health, Inc. Ceapro, Inc. Celgene Corp. Centene Corp. Cephalon, Inc. Chugai Pharmaceutical Co., Ltd. CK Life Sciences International (Holdings), Inc. Cornerstone Research & Development Inc. CTI BioPharma Corp. Domain Therapeutics SA Emd Millipore Corporation Emd Serono Inc. Endo International Plc Evotec AG GlaxoSmithKline Plc Janssen Biotech, Inc. JHL Biotech, Inc. Johnson & Johnson Laboratoire Theramex Lonza Group AG McKesson Corp. Merck KGaA MorphoSys AG Motif Bio Plc Myrexis, Inc. NBTY, Inc. Neptune Technologies & Bioresources, Inc. Nexvet Biopharma PLC Nordion Inc Novartis AG Opexa Therapeutics, Inc. Otsuka Pharmaceutical Co. Ltd. Owens & Minor, Inc. Panacos Pharmaceuticals, Inc. Pfizer Inc. Pharma Mar SA Premier Healthcare Alliance L.P. Quanterix Corp. Samsung BioLogics Co., Ltd. Sangers (Northern Ireland) Limited Sanofi Spectrum Pharmaceuticals, Inc. Taiho Pharmaceutical Co. Ltd. Takeda Pharmaceutical Co., Ltd. UnitedHealth Group, Inc. Verastem, Inc. Vertex Pharmaceuticals, Inc. Windtree Therapeutics, Inc. Zogenix, Inc.? To see a report overview please email Sara Peerun on sara.peerun@visiongain.com SOURCE Visiongain Ltd |
||
|
||
Copyright 2017 PR Newswire Association LLC. | Back to overview list |